EP-2060: Correlation of imaging data with knownpredictive/prognostic factors in Oropharyngeal cancer  by Lynch, J. et al.
S972                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
fractionated radiation treatment is assumed to be decisive 
for treatment success. [18F]-Fluoro-Misonidazole PET (F-
MISO-PET) allows noninvasive assessment of hypoxia during 
treatment. The purpose of the present study was to 
noninvasively assess the time course of tumor hypoxia. 
 
Material and Methods: A prospective serial imaging study 
was conducted in patients undergoing definitive 
chemoradiation (dRCTx, total dose 70Gy) for locally 
advanced HNSCC, accompanied by cisplatin in weeks 1, 4 and 
7. Tumor hypoxia was assessed by F-MISO-PET by static scans 
acquired 2.5 h p.i. Tumor volumes were determined for FDG 
PET/CT scans and the coregistered F-MISO/CT scans. At 
baseline MRI, FDG-PET/CT and F-MISO-PET were acquired 
(week 0). Additional F-MISO-PET/CT scans were acquired in 
treatment weeks 2 and 5. Normal sample distribution was 
confirmed with Shapiro-Wilk test. Unpaired t-test analysis of 
the mean SUVmax(tumor)/SUVmean(muscle) ratios of F-MISO-
PET in weeks 0, 2 and 5 were performed. Significance-level 
was defined as p<0.005. 
 
Results: Between 2012 and 2014 18 patients (16 men, two 
women, mean age 60 years), treated for HNSCC with dRCTx 
were included. All received a total dose of 70 Gy in 35 
fractions. Concomitant cisplatin chemotherapy was 
administered in weeks 1, 4 and 7. 14 patients had all F-MISO-
PET scans, while 4 had two F-MISO-PET scans (week 0, 5). 
The mean follow-up time was 14.6 months (range: 4 - 28 
months). Mean SUVmax(tumor)/SUVmean(muscle) in weeks 0, 
2 and 5 were 1.9 (n=18, SD ± 0.1), 1.5 (n=14, SD ± 0.1) and 
1.2 (n=18, SD ± 0.1), respectively. Unpaired t-test for 
SUVmax(tumor)/SUVmean(muscle) between week 0 and 5 
was performed, showing a singnificant decrease (p<0.0001). 
Between weeks 0 and 2 (p=0.0346) and between weeks 2 and 
5 the decrease again was highly significant (p=0.0113). In two 
patients no residual hypoxia was measured in week two, 
resulting in SUVmax(tumor)/SUVmean(muscle) =1.0. In week 
5 this was found in seven patients. In two patients hypoxia 
had increased in week 2 but decreased in week 5 compared 
to pre-treatment measurements. In one patient hypoxia had 
increased by the end of treatment.  
 
 
Conclusion: Differences in hypoxia between weeks 0-2, 2-5 
and 0- 5, respectively, show statistical significance. This is 
crucial in the process of re-oxygenation. As concluded in 
previous works, change of treatment strategy, e.g. by means 
of dose escalation might be most efficient early during 
treatment. However further analysis, with more patients and 
correlation to disease-free and overall-survival are needed. 
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Purpose or Objective: There is increasing interest in 
maximising data extraction from the multimodality imaging 
performed in cancer patients in order to predict treatment 
outcomes. This is particularly relevant in Oropharyngeal 
cancer where concomitant chemoradiotherapy is the 
standard treatment in stage III and IV disease but there is 
significant variation in patient outcomes and both treatment 
intensification and de-intensification strategies are being 
investigated.  
The aim of this prospective pilot study was to look at how 
data obtained from pre- and per-treatment 18F-FDG-PET/CT 
scans and textural features from pre- and per-treatment 
contrast enhanced planning CT scans correlated with known 
prognostic indicators including smoking history and HPV 
status.  
 
Material and Methods: Eligible patients included those 
undergoing primary concomitant chemoradiotherapy for 
Stage III/IV SCC of the Oropharynx. Each patient underwent a 
contrast enhanced planning CT and an 18F-FDG-PET/CT scan 
immobilised in the treatment position prior to the start of 
treatment and then again after 8-10 fractions of 
radiotherapy. The SUVmax and SUVmean were recorded on 
both the pre- and per- treatment 18F-FDG-PET/CT. Texture 
analysis was performed using TexRad software on both the 
pre- and per-treatment planning CT scans. The smoking 
history for each patient was established on enrolment to the 
study and HPV status was determined using p16 IHC on biopsy 
of the primary tumour. Ethical approval was gained from the 
relevant bodies. 
 
Results: Eighteen patients were recruited. HPV status was 
positive in 13 patients and negative in 5 patients. The 
SUVmax/mean in HPV negative patients was 21.6/13.3 on the 
pre-treatment 18F-FDG-PET/CT versus 15.2/10.5 for HPV 
positive patients (p= 0.09/0.25). Pre-treatment CT texture 
analysis showed a difference in the normalised entropy 
between the two groups with a significant difference 
detected using the smallest filter (p=0.04). The 
SUVmax/mean on the pre-treatment 18F-FDG-PET/CT for 
patients with no or minimal smoking history (<10 years) was 
13.7/9.5 versus 19.1/12.9 for those with a smoking history of 
>10years (p= 0.1/0.13). No significant difference in the 
entropy/entropy ratio between the two groups was detected. 
No significant differences were shown in the change in SUV or 
entropy ratio between the pre-and per-treatment scans in 
any of the groups. 
 
Conclusion: These results suggest differences in the imaging 
characteristics between patients in different prognostic 
categories may be detected at the pre-treatment stage and 
are worthy of further investigation in a larger patient cohort 
and may in the future add further information to that 
provided by the molecular profiling of tumours. This study 
did not show any significant differences in the data obtained 
between patients in terms of their early response to 
treatment however this data can be revisited once follow up 
data for this patient cohort matures. 
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Purpose or Objective: This study looking for the prognosis 
value of over-expression of EGFR and/or COX-2 in patients 
with locally advanced squamous cervical carcinoma (LASC). 
 
